138 related articles for article (PubMed ID: 33908053)
21. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma.
Larkin J; Ascierto PA; Dréno B; Atkinson V; Liszkay G; Maio M; Mandalà M; Demidov L; Stroyakovskiy D; Thomas L; de la Cruz-Merino L; Dutriaux C; Garbe C; Sovak MA; Chang I; Choong N; Hack SP; McArthur GA; Ribas A
N Engl J Med; 2014 Nov; 371(20):1867-76. PubMed ID: 25265494
[TBL] [Abstract][Full Text] [Related]
22. Vemurafenib in Chinese patients with BRAF
Si L; Zhang X; Xu Z; Jiang Q; Bu L; Wang X; Mao L; Zhang W; Richie N; Guo J
BMC Cancer; 2018 May; 18(1):520. PubMed ID: 29724167
[TBL] [Abstract][Full Text] [Related]
23. Effect of concomitant dosing with acid-reducing agents and vemurafenib dose on survival in patients with BRAF
Lewis K; Hauschild A; Larkin J; Ribas A; Flaherty KT; McArthur GA; Dréno B; McKenna E; Zhu Q; Mun Y; Ascierto PA
Eur J Cancer; 2019 Jul; 116():45-55. PubMed ID: 31173962
[TBL] [Abstract][Full Text] [Related]
24. Effects of pharmacogenetic variants on vemurafenib-related toxicities in patients with melanoma.
Goey AK; With M; Agema BC; Hoop EO; Singh RK; van der Veldt AA; Mathijssen RH; van Schaik RH; Bins S
Pharmacogenomics; 2019 Dec; 20(18):1283-1290. PubMed ID: 31829834
[No Abstract] [Full Text] [Related]
25. Effect of Itraconazole, a Potent CYP3A4 Inhibitor, on the Steady-State Pharmacokinetics of Vemurafenib in Patients With BRAF
Zhang W; Mathisen M; Goodman GR; Forbes H; Song Y; Bertran E; Demidov L; Shin SJ
Clin Pharmacol Drug Dev; 2021 Jan; 10(1):39-45. PubMed ID: 32602215
[TBL] [Abstract][Full Text] [Related]
26. New primary melanoma in a patient under triple therapy with vemurafenib, cobimetinib, and atezolizumab for metastatic melanoma.
Diamantopoulos PT; Lakiotaki E; Kyriakakis G; Gogas H
Melanoma Res; 2020 Apr; 30(2):206-208. PubMed ID: 31157737
[TBL] [Abstract][Full Text] [Related]
27. Population pharmacokinetics and dosing implications for cobimetinib in patients with solid tumors.
Han K; Jin JY; Marchand M; Eppler S; Choong N; Hack SP; Tikoo N; Bruno R; Dresser M; Musib L; Budha NR
Cancer Chemother Pharmacol; 2015 Nov; 76(5):917-24. PubMed ID: 26365290
[TBL] [Abstract][Full Text] [Related]
28. Extended 5-Year Follow-up Results of a Phase Ib Study (BRIM7) of Vemurafenib and Cobimetinib in
Ribas A; Daud A; Pavlick AC; Gonzalez R; Lewis KD; Hamid O; Gajewski TF; Puzanov I; Wongchenko M; Rooney I; Hsu JJ; Yan Y; Park E; McArthur GA
Clin Cancer Res; 2020 Jan; 26(1):46-53. PubMed ID: 31732523
[TBL] [Abstract][Full Text] [Related]
29. Comparative efficacy of combination immunotherapy and targeted therapy in the treatment of BRAF-mutant advanced melanoma: a matching-adjusted indirect comparison.
Atkins MB; Tarhini A; Rael M; Gupte-Singh K; O'Brien E; Ritchings C; Rao S; McDermott DF
Immunotherapy; 2019 May; 11(7):617-629. PubMed ID: 30852924
[TBL] [Abstract][Full Text] [Related]
30. Modeled Prognostic Subgroups for Survival and Treatment Outcomes in BRAF V600-Mutated Metastatic Melanoma: Pooled Analysis of 4 Randomized Clinical Trials.
Hauschild A; Larkin J; Ribas A; Dréno B; Flaherty KT; Ascierto PA; Lewis KD; McKenna E; Zhu Q; Mun Y; McArthur GA
JAMA Oncol; 2018 Oct; 4(10):1382-1388. PubMed ID: 30073321
[TBL] [Abstract][Full Text] [Related]
31. Profile of vemurafenib-induced severe skin toxicities.
Peuvrel L; Quéreux G; Saint-Jean M; Brocard A; Nguyen JM; Khammari A; Knol AC; Varey E; Dréno B
J Eur Acad Dermatol Venereol; 2016 Feb; 30(2):250-7. PubMed ID: 26524690
[TBL] [Abstract][Full Text] [Related]
32. Cardiac toxicity of combined vemurafenib and cobimetinib administration
.
Fiocchi R; Gori M; Taddei F; Trevisani L; Gallo M; Eleftheriou G
Int J Clin Pharmacol Ther; 2019 May; 57(5):259-263. PubMed ID: 30704555
[TBL] [Abstract][Full Text] [Related]
33. A first-in-human phase I study to evaluate the MEK1/2 inhibitor, cobimetinib, administered daily in patients with advanced solid tumors.
Rosen LS; LoRusso P; Ma WW; Goldman JW; Weise A; Colevas AD; Adjei A; Yazji S; Shen A; Johnston S; Hsieh HJ; Chan IT; Sikic BI
Invest New Drugs; 2016 Oct; 34(5):604-13. PubMed ID: 27424159
[TBL] [Abstract][Full Text] [Related]
34. Plasma vemurafenib exposure and pre-treatment hepatocyte growth factor level are two factors contributing to the early peripheral lymphocytes depletion in BRAF-mutated melanoma patients.
Puszkiel A; White-Koning M; Dupin N; Kramkimel N; Thomas-Schoemann A; Noé G; Chapuis N; Vidal M; Goldwasser F; Chatelut E; Blanchet B
Pharmacol Res; 2016 Nov; 113(Pt A):709-718. PubMed ID: 27378568
[TBL] [Abstract][Full Text] [Related]
35. Custo-utilidade de terapias-alvo comparadas à dacarbazina para o tratamento de primeira linha do melanoma avançado não-cirúrgico e metastático no Sistema Único de Saúde do Brazil.
Guerra RL; Corrêa FM; Fernandes RRA; Zimmerman IR
Value Health Reg Issues; 2019 Dec; 20():103-109. PubMed ID: 31174179
[TBL] [Abstract][Full Text] [Related]
36. [Cobimetinib/vemurafenib-associated bilateral serous retinopathy: a case report].
Kastl G
Ophthalmologe; 2019 Aug; 116(8):785-788. PubMed ID: 30357465
[TBL] [Abstract][Full Text] [Related]
37. Estimated Cost-effectiveness of Atezolizumab Plus Cobimetinib and Vemurafenib for Treatment of BRAF V600 Variation Metastatic Melanoma.
Cai C; Yunusa I; Tarhini A
JAMA Netw Open; 2021 Nov; 4(11):e2132262. PubMed ID: 34762112
[TBL] [Abstract][Full Text] [Related]
38. Efficacy of intermittent combined RAF and MEK inhibition in a patient with concurrent BRAF- and NRAS-mutant malignancies.
Abdel-Wahab O; Klimek VM; Gaskell AA; Viale A; Cheng D; Kim E; Rampal R; Bluth M; Harding JJ; Callahan MK; Merghoub T; Berger MF; Solit DB; Rosen N; Levine RL; Chapman PB
Cancer Discov; 2014 May; 4(5):538-45. PubMed ID: 24589925
[TBL] [Abstract][Full Text] [Related]
39. Vemurafenib in patients with BRAF V600E mutation-positive advanced melanoma.
Ravnan MC; Matalka MS
Clin Ther; 2012 Jul; 34(7):1474-86. PubMed ID: 22742884
[TBL] [Abstract][Full Text] [Related]
40. [Vemurafenib-induced radiation recall dermatitis].
Greliak A; Le Guern A; Bataille M; Lebas D; Wiart T; Modiano P
Ann Dermatol Venereol; 2019 May; 146(5):382-384. PubMed ID: 30981540
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
